Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | Tanezumab | Chronic low back pain | Phase 3 | Subcutaneous | Orthopedic | |
| Eli Lilly and Company | Lebrikizumab | Moderate-to-severe atopic dermatitis | Phase 3 | Data Released | Subcutaneous | Immunology |
| Eli Lilly and Company | Tirzepatide - (SURMOUNT-4) | Obesity or overweight with weight-related comorbidities | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Eli Lilly and Company | VTX3232 | Obesity and cardiometabolic risk factors | Phase 2 | Data Released | Oral | Endocrinology |
| Eli Lilly and Company | Insulin efsitora alfa (efsitora) - (QWINT-2 and QWINT-4) | Type 2 diabetes | Phase 3 | Data Released | Subcutaneous injection | Endocrinology |
| Eli Lilly and Company | PNT2003 | Neuroendocrine Tumors (NETs) | Phase 3 | Ongoing | Subcutaneous | Oncology |
| Eli Lilly and Company | Retatrutide - (TRIUMPH-4) | Osteoarthritis pain of the knee and overweight or obesity | Phase 3 | Data Released | Subcutaneous | Orthopedic |
| Eli Lilly and Company | Tirzepatide - (SYNERGY-NASH) | Nonalcoholic steatohepatitis (NASH), Metabolic dysfunction-associated steatohepatitis (MASH) | Phase 3 | Trial Planned | Subcutaneous | Gastroenterology |
